High frequency of BRAF mutations in nevi
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
To evaluate the timing of mutations in BRAF (v-raf murine sarcoma viral oncogene homolog B1) during melanocytic neoplasia, we carried out mutation analysis on microdissected melanoma and nevi samples. We observed mutations resulting in the V599E amino-acid substitution in 41 of 60 (68%) melanoma metastases, 4 of 5 (80%) primary melanomas and, unexpectedly, in 63 of 77 (82%) nevi. These data suggest that mutational activation of the RAS/RAF/MAPK pathway in nevi is a critical step in the initiation of melanocytic neoplasia but alone is insufficient for melanoma tumorigenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, the BRAF oncogenic mutation found in more than half of all malignant cutaneous melanomas is commonly found also in non-malignant nevi, where it causes oncogene-induced senescence exemplified by high levels of CDKN2A and SA-β-gal expression225–227.”
From SenNet recommendations for detecting senescent cells in different tissues (2024) · cites this paper as [226]
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Tissue microarrays for high-throughput molecular profiling of tumor specimens
Kononen, J., Bubendorf, L., Kallionimeni, A., Bärlund, M., Schraml, P., Leighton, S., Torhorst, J., Mihatsch, M. J., Sauter, G., & Kallionimeni, O.-P. (1998) · Nature Medicine · doi:10.1038/nm0798-844 · Cited by 4,099
Busca, R. (2000) · The EMBO Journal · doi:10.1093/emboj/19.12.2900 · Cited by 326
The Regulation of Normal Melanocyte Proliferation
Halaban, R. (2000) · Pigment Cell Research · doi:10.1034/j.1600-0749.2000.130103.x · Cited by 179
Research works printed but not linked: 2
- Armstrong, B.K. & English, D.R. in Cancer Epidemiology and Prevention (Oxford University Press, New York, 1996).
- Elder, D.E. & Murphy, G.F. in Atlas of Tumor Pathology: Melanocytic Tumors of the Skin 5–101 (Armed Forces Insititute of Pathology, Washington, DC, 1991).
Cited by
Items 601–700 of 1,001
BRAF kinase in melanoma development and progression
DeLuca, A. M., Srinivas, A., & Alani, R. M. (2008) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399408000604 · Cited by 58
An update on the implications of cyclin D1 in melanomas
González‐Ruiz, L., González‐Moles, M. Á., González‐Ruiz, I., Ruiz‐Ávila, I., Ayén, Á., & Ramos‐García, P. (2020) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12874 · Cited by 49
Corrales, E., Levit‐Zerdoun, E., Metzger, P., Mertes, R., Lehmann, A., Münch, J., Lemke, S., Kowar, S., & Boerries, M. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00989-y · Cited by 54
“These genetic alterations are considered as one of the main drivers of the malignant transformation of melanocytes [39].”
BackgroundHansson, J. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-6448-9_13 · Cited by 57
Casula, M., Muggiano, A., Cossu, A., Budroni, M., Caracò, C., Ascierto, P. A., Pagani, E., Stanganelli, I., Canzanella, S., Sini, M. C., et al. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-352 · Cited by 55
“Presence of BRAF mutations in benign and dysplastic nevi [39] supports the hypothesis that activation of the NRASBRAF-ERK pathway is not sufficient to induce the malignant process and fully transform proliferating melanocytes, but requires additional, cooperating de-regulative events.”
Backgroundvan Tuyn, J., Jaber-Hijazi, F., MacKenzie, D., Cole, J. J., Mann, E., Pawlikowski, J. S., Rai, T. S., Nelson, D. M., McBryan, T., Ivanov, A., et al. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.05.030 · Cited by 51
“The same mutations are also commonly found in benign nevi (or moles) (Omholt et al., 2002; Pollock et al., 2003).”
BackgroundBarutello, G., Rolih, V., Arigoni, M., Tarone, L., Conti, L., Quaglino, E., Buracco, P., Cavallo, F., & Riccardo, F. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030799 · Cited by 75
Calapre, L., Giardina, T. M., Robinson, C., Reid, A. L., Al‐Ogaili, Z., Pereira, M. R., McEvoy, A. C., Warburton, L., Hayward, N. K., Khattak, M. A., et al. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12391 · Cited by 53
“Recurring hotspot mutations in the V600 codon of BRAF or Q61 codon of NRAS are the most prevalent and occur in approximately 35–50% and 10–25% of melanomas, respectively (Pollock et al., 2002; TCGA, 2015; Tsao et al., 2012).”
BackgroundSelf-citationBRAF Kinase Gene V599E Mutation in Growing Melanocytic Lesions
Loewe, R. P., Kittler, H., Fischer, G., Faé, I., Wolff, K. S., & Petzelbauer, P. (2004) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2004.23402.x · Cited by 49
Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas
Kannengiesser, C., Spatz, A., Michiels, S., Eychène, A., Dessen, P., Lazar, V., Winnepenninckx, V. J. L., Lesueur, F., Druillennec, S., Robert, C., et al. (2008) · Molecular Oncology · doi:10.1016/j.molonc.2008.01.002 · Cited by 50
Bioorthogonal reactions challenged: DNA templated native chemical ligation during PCR
Roloff, A., & Seitz, O. (2012) · Chemical Science · doi:10.1039/c2sc20961f · Cited by 49
Christensen, C., & Guldberg, P. (2005) · Oncogene · doi:10.1038/sj.onc.1208758 · Cited by 48
Schultz, J., Lorenz, P., Ibrahim, S. M., Kundt, G., Gross, G., & Kunz, M. (2008) · Molecular Carcinogenesis · doi:10.1002/mc.20452 · Cited by 52
Precision medicine driven by cancer systems biology
Filipp, F. V. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9662-4 · Cited by 59
“Early on, identification of activating point mutations in the mitogen-activated protein kinase (MAPK) pathway in B-Raf proto-oncogene (BRAF, serine/threonine kinase, Gene ID: 673) [36, 37] and neuroblastoma RAS viral oncogene homolog (NRAS, Gene ID: 4893) made it possible to match genotyped kinase mutations with preci…”
BackgroundMelanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells
Testa, U., Castelli, G., & Pelosi, E. (2017) · Medical Sciences · doi:10.3390/medsci5040028 · Cited by 59
“Some mutations present in melanoma, such as BRAF, NRAS, GNAQ, or GNA11, and rearrangements in fusion kinases, have been observed in benign nevi, and therefore represent events acquired early during tumor progression [96].”
BackgroundBRAF Gene Mutations Are Rare Events in Gastroenteropancreatic Neuroendocrine Tumors
Tannapfel, A., Vomschloß, S., Karhoff, D., Markwarth, A., Hengge, U. R., Wittekind, C., Arnold, R., & Hörsch, D. (2005) · American Journal of Clinical Pathology · doi:10.1309/yqbr-9c05-ru4d-d3rn · Cited by 48
Metastatic melanoma – a review of current and future drugs
Velho, T. R. (2012) · Drugs in Context · doi:10.7573/dic.212242 · Cited by 54
“Moreover, up to 82% of benign nevi have been shown to possess activating BRAF mutations, suggesting that activation of the mitogen-activated protein kinase (MAPK) pathway is necessary for melanoma development but not sufficient for malignant transformation [91].”
Melanoma, long wavelength ultraviolet and sunscreens: Controversies and potential resolutions
Lund, L. P., & Timmins, G. S. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.01.007 · Cited by 56
Co-development of a companion diagnostic for targeted cancer therapy
Cheng, S., Koch, W. H., & Wu, L. (2012) · New Biotechnology · doi:10.1016/j.nbt.2012.02.002 · Cited by 53
Genetics of melanoma predisposition
Lin, J., Hocker, T. L. H., Singh, M., & Tsao, H. (2008) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2008.08682.x · Cited by 48
Molecular alterations at chromosome 9p21 in melanocytic naevi and melanoma
Sini, M. C., Manca, A., Cossu, A., Budroni, M., Botti, G., Ascierto, P. A., Cremona, F., Muggiano, A., D’Atri, S., Casula, M., et al. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.08310.x · Cited by 54
Packham, D., Ward, R. L., Lin, V. A., Hawkins, N. J., & Hitchins, M. P. (2009) · Diagnostic Molecular Pathology · doi:10.1097/pdm.0b013e318182af52 · Cited by 50
“BRAF mutations are also found in precancerous lesions, indicating that they occur early in tumorigenesis.(4,5) The valine to glutamate mutation at BRAF residue 600 (V600E), induced by the T1799A nucleotide transversion within exon 15, accounts for most (>90%) of the BRAF mutations in cancer.”
BackgroundSilva, J. M., Bulman, C., & McMahon, M. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0224-t · Cited by 48
“org Mol Cancer Res; 12(3) March 2014 453”
BackgroundInfluentialChoi, S.-Y., Bin, B.-H., Kim, W., Lee, E., Lee, T. R., & Cho, E. (2018) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2018.02.016 · Cited by 55
Cutaneous melanoma: A model to study cancer metastasis
Leong, S. P. L., Gershenwald, J. E., Soong, S.-J., Schadendorf, D., Tarhini, A. A., Agarwala, S. S., Hauschild, A., Soon, C. W. M., DAUD, A. I., & Kashani‐Sabet, M. (2011) · Journal of Surgical Oncology · doi:10.1002/jso.21816 · Cited by 50
Pawlikowski, J. S., Adams, P. D., & Nelson, D. M. (2013) · Journal of Cell Science · doi:10.1242/jcs.109728 · Cited by 70
Qi, R.-Q., He, L., Zheng, S. G., Hong, Y., Ma, L., Zhang, S., Zhao, L., Guo, X., Wang, Y., Yu, J.-Y., et al. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.405 · Cited by 48
“8%, comparable to that in populations of other ethnicities (Pollock et al., 2003; Poynter et al., 2006).”
BackgroundInfluentialRUNX2 is overexpressed in melanoma cells and mediates their migration and invasion
Boregowda, R. K., Olabisi, O. O., Abushahba, W., Jeong, B., Haenssen, K. K., Chen, W., Chekmareva, M. A., Lasfar, A., Foran, D. J., Goydos, J. S., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.03.011 · Cited by 52
“in BRAF observed in a large majority of nevi [42] likely plays a role in the induction of the OIS program in melanocytes by yet undefined mechanisms [43; 44; 45].”
BackgroundTargeted Molecular Therapy in Melanoma
Puzanov, I. J., & Flaherty, K. T. (2010) · Seminars in Cutaneous Medicine and Surgery · doi:10.1016/j.sder.2010.06.005 · Cited by 52
RetractedMelanoma Biology and the Promise of Zebrafish
Ceol, C. J., Houvras, Y. J., White, R. M., & Zon, L. I. (2008) · Zebrafish · doi:10.1089/zeb.2008.0544 · Cited by 55
“BRAF mutations are found not only in melanomas but also in nevi, 81 indicating that mutant BRAF cooperates with other genetic lesions in tumor formation.”
KRAS mutation testing in clinical practice
Perincheri, S., & Hui, P. (2014) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2015.986102 · Cited by 48
Delston, R. B., Matatall, K. A., Sun, Y., Onken, M. D., & Harbour, J. W. (2010) · Oncogene · doi:10.1038/onc.2010.442 · Cited by 52
Hocker, T. L. H., Alikhan, A., Comfere, N. I., & Peters, M. S. (2012) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2012.09.031 · Cited by 46
Kim, Y. H., Choi, Y. W., Han, J. H., Lee, J., Soh, E. Y., Park, S. H., Kim, J., & Park, T. J. (2014) · Neoplasia · doi:10.1016/j.neo.2014.10.005 · Cited by 52
“B-RafV600E has also been reported in other cancers such as melanoma and colorectal and ovarian cancers [4–7] and known to be involved in early stage of carcinogenesis [4,5,8].”
BackgroundUpdates in Therapy for Advanced Melanoma
Singh, B. P., & Salama, A. K. S. (2016) · Cancers · doi:10.3390/cancers8010017 · Cited by 54
“discovery that a large number of melanomas harbor activating mutations in BRAF [14–16].”
BackgroundEtnyre, D., Stone, A. L., Fong, J., Jacobs, R. J., Uppada, S. B., Botting, G. M., Rajanna, S., Moravec, D. N., Shambannagari, M. R., Crees, Z. D., et al. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.29451 · Cited by 51
Bond, C., & Whitehall, V. (2018) · Gastroenterology Research and Practice · doi:10.1155/2018/9250757 · Cited by 54
Current Strategies in Overcoming Resistance of Cancer Cells to Apoptosis Melanoma as a Model
Hersey, P., Zhuang, L., & Zhang, X. D. (2006) · International review of cytology · doi:10.1016/s0074-7696(06)51004-6 · Cited by 52
Epidermal Growth Factor Gene (EGF) Polymorphism and Risk of Melanocytic Neoplasia
James, M. R., Hayward, N. K., Dumenil, T. D., Montgomery, G. W., Martin, N. G., & Duffy, D. L. (2004) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2004.23305.x · Cited by 46
Self-citationAfter Nf1 loss in Schwann cells, inflammation drives neurofibroma formation
Fletcher, J. S., Pundavela, J., & Ratner, N. (2019) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdz045 · Cited by 54
Labelle-Côté, M., Dusseault, J., Ismaïl, S., Picard-Cloutier, A., Siegel, P. M., & Larose, L. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-443 · Cited by 52
“From a molecular point of view, oncogenic activation of the mitogen-activated protein kinase (MAPK) pathway, due to somatic mutations in B-RAF (V600E), is frequently observed in melanoma (70%) [4].”
BackgroundVenesio, T., Chiorino, G., Balsamo, A., Zaccagna, A., Petti, C., Scatolini, M., Pisacane, A. M., Sarotto, I., Picciotto, F., & Risio, M. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.41 · Cited by 47
“Among the genes controlling the MAPK pathway, BRAF has been found highly mutated in a variable percentage of nevi and melanomas”
BackgroundBennani-Lahlou, M., Mateus, C., Escudier, B. J., Massard, C., Soria, J., Spatz, A., & Robert, C. (2008) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/j.annder.2008.04.016 · Cited by 47
Towards new therapeutic approaches for malignant melanoma
Pacheco, I., Buzea, C., & Tron, V. A. (2011) · Expert Reviews in Molecular Medicine · doi:10.1017/s146239941100202x · Cited by 54
Shekar, S. N., Duffy, D. L., Youl, P., Baxter, A. J., Kvaskoff, M., Whiteman, D. C., Green, A. C., Hughes, M. C. B., Hayward, N. K., Coates, M. S., et al. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.48 · Cited by 47
“Others have found that mutations in the BRAF gene are more common in melanomas occurring on intermittently sun-exposed skin (Pollock et al., 2003; Rivers, 2004).”
BackgroundSelf-citationDroplet Digital PCR for Mutation Detection in Formalin-Fixed, Paraffin-Embedded Melanoma Tissues
McEvoy, A. C., Wood, B. A., Ardakani, N. M., Pereira, M. R., Pearce, R., Cowell, L., Robinson, C., Grieu‐Iacopetta, F., Spicer, A. J., Amanuel, B., et al. (2018) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2017.11.009 · Cited by 49
Molecular markers of circulating melanoma cells
Medic, S., Pearce, R. L., Heenan, P. J., & Ziman, M. R. (2006) · Pigment Cell Research · doi:10.1111/j.1600-0749.2006.00356.x · Cited by 52
Self-citationSkp2 Regulates G2/M Progression in a p53-dependent Manner
Hu, R., & Aplin, A. E. (2008) · Molecular Biology of the Cell · doi:10.1091/mbc.e07-11-1137 · Cited by 47
Eye Cancer: Unique Insights into Oncogenesis The Cogan Lecture
Harbour, J. W. (2006) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.05-1291 · Cited by 52
“Second, for the reasons discussed earlier, disruption of the Rb pathway is probably an early event in melanoma initiation, being required for melanocytes to re-enter the cell cycle before acquiring additional mutations.(74,93) A few recurring chromosomal alterations are associated with increased risk of metastasis, in…”
BackgroundDadzie, O. E., Yang, S., Emley, A., Keady, M., Bhawan, J., & Mahalingam, M. (2009) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2008.08887.x · Cited by 46
Targeting anti-apoptotic pathways eliminates senescent melanocytes and leads to nevi regression
Kohli, J. S., Chen, G., Fitsiou, E., Doepner, M., Brandenburg, S. M., Faller, W. J., Ridky, T. W., & Demaria, M. (2022) · Nature Communications · doi:10.1038/s41467-022-35657-9 · Cited by 46
“%) derives from an activating mutation in the gene BRAF , a serine/threonine protein kinase that plays an important role in transducing growth factor signals to the nucleus 3,4 .”
Primary Anorectal Melanoma: An Update
Carcoforo, P., Raiji, M. T., Palini, G. M., Pedriali, M., Maestroni, U. V., Soliani, G., Detroia, A., Zanzi, M. V., Manna, A. L., Crompton, J. G., et al. (2012) · Journal of Cancer · doi:10.7150/jca.5187 · Cited by 47
FOXD3 Regulates Migration Properties and Rnd3 Expression in Melanoma Cells
Katiyar, P., & Aplin, A. E. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0454 · Cited by 47
“Notably, the levels of phospho-ERK1/2 (pERK1/2) are low in nevi, likely due to feedback inhibition (6).”
The genetic heterogeneity and mutational burden of engineered melanomas in zebrafish models
Yen, J. L., White, R. M., Wedge, D. C., Loo, P. V., de Ridder, J., Capper, A., Richardson, J., Jones, D., Raine, K. M., Watson, I. R., et al. (2013) · Genome biology · doi:10.1186/gb-2013-14-10-r113 · Cited by 49
“; licensee BioMed Central Ltd Commons Attribution License (http://creativec reproduction in any medium, provided the or nevi with BRAF or NRAS mutations remain benign for decades [4].”
Backgroundde la Fouchardière, A., Tee, M. K., Peternel, S., Valdebran, M., Pissaloux, D., Tirode, F., BUSAM, K. J., LeBoit, P. E., McCalmont, T. H., Bastian, B. C., et al. (2020) · Modern Pathology · doi:10.1038/s41379-020-00678-6 · Cited by 44
Gallagher, S. J., Thompson, J. F., Indsto, J. O., Scurr, L. L., Lett, M., Gao, B.-F., Dunleavey, R., Mann, G. J., Kefford, R. F., & Rizos, H. (2008) · Neoplasia · doi:10.1593/neo.08702 · Cited by 48
“Up to 80% of benign nevi [21] and 25% to 66% of melanomas contain activating B-RAF mutations [22,23].”
BackgroundBenign Nodal Nevi Frequently Harbor the Activating V600E BRAF Mutation
Taube, J. M., Begum, S., Shi, C., Eshleman, J. R., & Westra, W. H. (2009) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31818a64fb · Cited by 44
“First, mutational activation of the BRAF oncogene is very prevalent in cutaneous melanomas, occurring in up to 80% of primary melanomas.(10,23) Second, these mutations persist in melanomas that have metastasized.”
BackgroundDetection of Mutant BRAF Alleles in the Plasma of Patients with Metastatic Melanoma
Yancovitz, M., Yoon, J., Mikhail, M., Gai, W., Shapiro, R. L., Berman, R. S., Pavlick, A. C., Chapman, P. B., Osman, I., & Polsky, D. (2007) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2007.060135 · Cited by 44
Zembowicz, A. (2017) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2017.05.001 · Cited by 44
Raf Kinase Inhibitors in Oncology
Strumberg, D., & Seeber, S. (2005) · Oncology Research and Treatment · doi:10.1159/000083373 · Cited by 44
Garamvölgyi, R., Dobos, J., Sipos, A., Boros, S., Illyés, E., Baska, F., Kékesi, L., Szabadkai, I., Szántai-Kis, C., Kéri, G., et al. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.12.001 · Cited by 43
Niu, Y., Li, S., Pan, D., Liu, H., & Yao, X. (2016) · Physical Chemistry Chemical Physics · doi:10.1039/c5cp06257h · Cited by 44
Kiuru, M. H., Tartar, D. M., Qi, L., Chen, D., Yu, L., Konia, T. H., McPherson, J. D., Murphy, W. J., & Fung, M. A. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.03.052 · Cited by 50
“This frequency of BRAF V600E is similar to that in prior reports.(2,6,7) Themean agewas 53.”
Lee, D. A., Cohen, J. A., Twaddell, W. S., Palacios, G. F., Gill, M., Levit, E., Halperin, A. J., Mones, J. M., BUSAM, K. J., Silvers, D. N., et al. (2006) · Cancer · doi:10.1002/cncr.21686 · Cited by 44
Pyrophosphorolysis Detects B-RAF Mutations in Primary Uveal Melanoma
Maat, W., Kılıç, E., Luyten, G. P. M., de Klein, A., Jager, M. J., Gruis, N. A., & van der Velden, P. A. (2008) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.07-0722 · Cited by 47
“80 consists of a GT —› AA substitution at position 1798-1799 and is also located in the serine/threonine kinase domain of B-RAF (Pollock et al., 2003).”
BackgroundRaman spectroscopy as an analytical tool for melanoma research
Brauchle, E., Noor, S., Holtorf, E., Garbe, C., Schenke‐Layland, K., & Busch, C. (2014) · Clinical and Experimental Dermatology · doi:10.1111/ced.12357 · Cited by 49
The 5th Edition of the World Health Organization Classification of Tumours of the Eye and Orbit
Milman, T., Grossniklaus, H. E., Goldman‐Lévy, G., Kivelä, T., Coupland, S. E., White, V. A., Mudhar, H. S., Eberhart, C. G., Verdijk, R. M., Heegaard, S., et al. (2023) · Ocular Oncology and Pathology · doi:10.1159/000530730 · Cited by 43
PP2A-B56α controls oncogene-induced senescence in normal and tumor human melanocytic cells
Mannava, S., Omilian, A. R., Wawrzyniak, J. A., Fink, E. E., Zhuang, D., Miecznikowski, J. C., Marshall, J. R., Soengas, M. S., Sears, R. C., Morrison, C. D., et al. (2012) · Oncogene · doi:10.1038/onc.2011.339 · Cited by 42
“Intriguingly, activating mutations in the same genes have been detected in several types of malignant melanomas but at lower frequencies (Pollock et al., 2003; Curtin et al., 2005; Maldonado et al., 2003), indicating that malignant melanomas that often originate from nevi must have developed…”
BackgroundInfluentialSmyth, P. C., Finn, S. P., Cahill, S., O’Regan, E. M., Flavin, R., O’Leary, J. J., & Sheils, O. M. (2005) · International Journal of Surgical Pathology · doi:10.1177/106689690501300101 · Cited by 42
“in a variety of human tissues [1], and their frequency varies from 80% in melanomas and nevi [2,3] to less than 10% in lung and colorectal tumors [4,5].”
BackgroundBRAF , NRAS , and GNAQ Mutations in Conjunctival Melanocytic Nevi
Francis, J. H., Grossniklaus, H. E., Habib, L. A., Marr, B. P., Abramson, D. H., & BUSAM, K. J. (2018) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.17-22517 · Cited by 42
Rather, R. A., Bhagat, M., & Singh, S. K. (2020) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2020.108321 · Cited by 46
Comparative Aspects of BRAF Mutations in Canine Cancers
Mochizuki, H., & Breen, M. (2015) · Veterinary Sciences · doi:10.3390/vetsci2030231 · Cited by 53
“The BRAF mutation was found in 82% of nevi in humans and in 17% of canine melanocytomas [11,26], suggesting the BRAF mutation and consequent MAPK activation may play an important role in the initiation of melanocytic neoplasms, but may be insufficient to cause malignant melanoma without additional molecular alteration…”
BackgroundMolecular Pathobiology of Uveal Melanoma
Ehlers, J. P., & Harbour, J. W. (2005) · International Ophthalmology Clinics · doi:10.1097/01.iio.0000195855.31324.db · Cited by 45
“The finding of mutations that disrupt the Rb pathway in benign cutaneous nevi suggests that Rb must be inhibited very early in the formation of melanocytic tumors.(68) Because Rb enforces cell-cycle exit in melanocytes,(64) this early disruption of Rb may be required to allow nascent neoplastic melanocytes to reenter…”
BackgroundSmorodinsky-Atias, K., Goshen‐Lago, T., Goldberg-Carp, A., Kadosh, D. M., Shir, A., Mooshayef, N., Beenstock, J., Karamansha, Y., Darlyuk‐Saadon, I., Livnah, O., et al. (2015) · Molecular Biology of the Cell · doi:10.1091/mbc.e15-07-0521 · Cited by 46
“Volume 27 March 15, 2016 Intrinsically active Erk1 is oncogenic | 1027 Meltzer, 2002; Pollock et al., 2003).”
BackgroundDifferential roles of the pRb and Arf/p53 pathways in murine naevus and melanoma genesis
Ferguson, B., Konrad Muller, H., Handoko, H. Y., Khosrotehrani, K., Beermann, F., Hacker, E., Peter Soyer, H., Bosenberg, M., & Walker, G. J. (2010) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00752.x · Cited by 41
“Importantly, BRAF or NRAS mutation is present in most naevi (Pollock et al., 2003), which are sometimes MM precursors (Grichnik, 2008).”
BackgroundAnaplastic Thyroid Cancer: Outcome and the Mutation/Expression Profiles of Potential Targets
Wu, H., Sun, Y., Ye, H., Yang, S., Lee, S. L., & Morenas, A. D. L. (2015) · Pathology & Oncology Research · doi:10.1007/s12253-014-9876-5 · Cited by 41
“BRAF mutation assay [20–22] Allele-specific PCRwas used for forward and reverse strand BRAF codon 600mutation assay.”
MethodSýkorová, V., Dvořáková, Š., Ryška, A., Včelák, J., Václavíková, E., Laco, J., Kodetova, D. N., Kodet, R., Cibula, A., Duskova, J., et al. (2010) · Journal of Endocrinological Investigation · doi:10.1007/bf03346593 · Cited by 41
McNeal, A. S., Belote, R. L., Zeng, H., Urquijo, M. A., Barker, K., Torres, R., Curtin, M. C., Shain, A. H., Andtbacka, R. H. I., Holmen, S. L., et al. (2021) · eLife · doi:10.7554/elife.70385 · Cited by 44
“The BRAF mutation is clonally present in ~ 80% of human melanocytic nevi (Pollock et al., 2003) and melanocytespecific expression of the oncogene is sufficient to induce nevus formation in mice (Dankort et al.”
Loss of maspin expression contributes to a more invasive potential in malignant melanoma
Denk, A., Bettstetter, M., Wild, P. J., Hoek, K. S., Bataille, F., Dietmaier, W., & Bosserhoff, A. (2007) · Pigment Cell Research · doi:10.1111/j.1600-0749.2007.00363.x · Cited by 41
Casorzo, L., Luzzi, C., Nardacchione, A., Picciotto, F., Pisacane, A. M., & Risio, M. (2005) · Melanoma Research · doi:10.1097/00008390-200506000-00003 · Cited by 41
C-Raf Is Associated with Disease Progression and Cell Proliferation in a Subset of Melanomas
Jilaveanu, L. B., Zito, C. R., Aziz, S. A., Conrad, P. J., Schmitz, J. C., Sznol, M., Camp, R. L., Rimm, D. L., & Kluger, H. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0198 · Cited by 41
“Because the MAPK pathway is also activated in melanomas that lack the B-Raf mutation, and because this mutation is found as frequently in atypical nevi as in melanomas, MAPK signaling is probably mediated by additional mechanisms (14, 15).”
BackgroundJørgensen, K., Holm, R., Mælandsmo, G. M., & Flørenes, V. A. (2003) · PubMed · Cited by 41
Regulation of LncRNAs in Melanoma and Their Functional Roles in the Metastatic Process
Melixetian, M. B., Pelicci, P. G., & Lanfrancone, L. (2022) · Cells · doi:10.3390/cells11030577 · Cited by 46
Koperek, O., Akin, E., Asari, R., Niederle, B., & Neuhold, N. (2013) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-013-1484-3 · Cited by 40
“Especially BRAF mutations were detected early in tumorigenesis [27, 35], but HIF-1α expression is more often seen in larger and more invasive PTC; thus, other regulators, e.”
BackgroundMAPK and Hippo signaling pathways crosstalk via the RAF-1/MST-2 interaction in malignant melanoma
Feng, R., Gong, J., Wu, L., Wang, L., Zhang, B., Liang, G., Zheng, H., & Xiao, H. (2017) · Oncology Reports · doi:10.3892/or.2017.5774 · Cited by 45
Heterotrimeric G Proteins as Therapeutic Targets in Drug Discovery
Li, J., Yang, G., Huang, J.-X., Strømgaard, K., Zhang, X., & Xiong, X. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01452 · Cited by 44
Miller, C. J., Cheung, M., Sharma, A. K., Clarke, L. E., Helm, K. F., Mauger, D. T., & Robertson, G. P. (2004) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2004.23468.x · Cited by 40
Plaça, M. L., Ambretti, S., Bonvicini, F., Venturoli, S., Bianchi, T., Varotti, C., Zerbini, M., & Musiani, M. (2005) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2005.06344.x · Cited by 43
Marrot, L., Belaïdi, J.-P., Jones, C., Perez, P., & Meunier, J.-R. (2004) · Photochemistry and Photobiology · doi:10.1562/2004-10-13-ra-343 · Cited by 37
Detection of the BRAF V600E mutation in melanocytic lesions using the ligase detection reaction
Turner, D. J., Zirvi, M., Barany, F., Elenitsas, R., & Seykora, J. T. (2005) · Journal of Cutaneous Pathology · doi:10.1111/j.0303-6987.2005.00338.x · Cited by 40
“However, this was somewhat tempered when screening of dermal, compound, and dysplastic nevi revealed an even higher frequency of the BRAF V600E mutation, at approximately 90%.(10) Taken together, this information supports a role for BRAF gene mutations in the early stages of melanocytic neoplasia; however, it does not…”
BackgroundMethodInfluentialMoschos, S. J., Kirkwood, J. M., & Konstantinopoulos, P. A. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.952 · Cited by 40
“Recent reports on the use of the less selective Raf kinase inhibitors (BAY 43-9006) in patients with metastatic melanoma are also promising [25] although the expression of B-Raf in nevi suggests that the evaluation of this intervention in precursor atypical nevi may be more appropriate, especially as selective B-Rafsp…”
BackgroundNarrative Review: BRAF Opens the Door for Therapeutic Advances in Melanoma
Flaherty, K. T. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-153-9-201011020-00008 · Cited by 40
“However, these mutations were much more common in melanoma and other melanocytic proliferations, occurring in more than one half of analyzed cases of nevi, primary invasive disease, and metastatic disease (12, 13).”
BackgroundBonner, M. Y., Karlsson, I. B., Rodolfo, M., Arnold, R. S., Vergani, E., & Arbiser, J. L. (2016) · Oncotarget · doi:10.18632/oncotarget.7289 · Cited by 40
“The majority of human melanomas express mutations in BRAF [1], and because of this mutation, much effort has gone into targeting BRAF and downstream pathways [2, 3].”
BackgroundLoss of miR-204 expression is a key event in melanoma
Galasso, M., Morris, Q., Minotti, L., Corrà, F., Zerbinati, C., Agnoletto, C., Baldassari, F., Fassan, M., Bartolazzi, A., Vecchione, A. M., et al. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0819-8 · Cited by 40
“BRAF and NRAS are frequently somatically mutated in melanoma [11, 13, 14], along with NF1, CDKN2A Fig.”
BackgroundJilaveanu, L. B., Zito, C. R., Lee, S. J., Nathanson, K. L., Camp, R. L., Rimm, D. L., Flaherty, K. T., & Kluger, H. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2280 · Cited by 39
The T1799A BRAF mutation is not a germline mutation in familial nonmedullary thyroid cancer
Xing, M. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02332.x · Cited by 39
The Mutagenic Impact of Environmental Exposures in Human Cells and Cancer: Imprints Through Time
Huber, A. R., van Hoeck, A., & van Boxtel, R. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.760039 · Cited by 43
“In 83% of skin naevi (common moles), oncogenic BRAF V600E mutations have been found (Pollock et al., 2003).”
BackgroundOxidative Stress and Autophagy as Key Targets in Melanoma Cell Fate
Catalani, E., Giovarelli, M., Zecchini, S., Perrotta, C., & Cervia, D. (2021) · Cancers · doi:10.3390/cancers13225791 · Cited by 38
“Mutations of NRAS, which are associated with an aggressive clinical course and a poor prognosis, occur in more than 20% of cutaneous melanoma patients [21].”
BackgroundExomic landscape of MED12 mutation‐negative and ‐positive uterine leiomyomas
Mäkinen, N., Vahteristo, P., Bützow, R. C., Sjöberg, J., & Aaltonen, L. A. (2013) · International Journal of Cancer · doi:10.1002/ijc.28410 · Cited by 40
“A similar pattern has been reported previously in the context of melanocytic nevi, which harbor specific missense mutations in BRAF (v-raf murine sarcoma viral oncogene homolog B1).(26) Indeed, such a narrow pattern of one prevailing activating mutation may be more feasible in genesis of benign, but not malignant tumo…”
BackgroundControversial aspects of oncogene-induced senescence
Bianchi-Smiraglia, A., & Nikiforov, M. A. (2012) · Cell Cycle · doi:10.4161/cc.22589 · Cited by 38
Metadata
- Authors
- Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., Salem, G., Pohida, T., Heenan, P., Duray, P., Kallioniemi, O., Hayward, N. K., Trent, J. M., & Meltzer, P. S.
- Affiliations
- National Institutes of Health (US)
- QIMR Berghofer Medical Research Institute (AU)
- The University of Western Australia (AU)
- Corresponding author
- Meltzer, Paul S.
- ORCID
- Venue
- Nature Genetics
- Published
- 2002-11-25
- Volume
- 33
- Issue
- 1
- Pages
- 19-20
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W1565041471
- Cited by
- 1,730
- References
- 4
- Citations by year
- 2026: 15 · 2025: 24 · 2024: 40 · 2023: 49 · 2022: 46 · 2021: 73 · 2020: 58 · 2019: 73 · 2018: 67 · 2017: 87 · 2016: 79 · 2015: 87 · 2014: 84 · 2013: 104 · 2012: 92
- FWCI
- 25.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Health Sciences › Medicine › Clinical Neurology › Neurofibromatosis and Schwannoma Cases
- Keywords
- BRAF mutation, melanocytic nevi, melanoma, melanoma metastasis, RAS/MAPK pathway, carcinogenesis
- MeSH terms
- Cell Transformation, Neoplastic, DNA Mutational Analysis, Gene Frequency, Humans, Melanoma, Nevus, Signal Transduction, Polymerase Chain Reaction, Genetic Predisposition to Disease, Mutation, Missense, Oncogene Proteins v-raf
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.